NuVasive Launches AttraX Putty

NuVasive, Inc. has announced the U.S. launch of its newest biologic, AttraX Putty. As indicated in the May 23, 2016 news release, “AttraX Putty is a next-generation, synthetic bone graft product indicated for use as an autograft extender in posterolateral spine surgery. The unique biotextured surface features of AttraX Putty helps drive regeneration of bone at the implanted site.”

“AttraX Putty is a synthetic, osteoconductive bone void filler for the repair of bone defects. A proprietary manufacturing process generates the AttraX Putty surface structure, which provides an instructive environment for mesenchymal stem cells (MSCs) to differentiate into bone-forming osteoblasts without added growth factors. Its unique bioresorbable material composition is designed to support an appropriate cell-mediated resorption rate. AttraX granules are combined with Alkylene Oxide Copolymer (AOC), a polymeric blend, which provides intraoperative flexibility allowing the clinician to mold the biologic into specific shapes as desired. When placed next to viable host bone, new bone will be deposited on the surface of the implant. The implant will be resorbed and replaced by bone during the natural process of bone remodeling.”

“We are excited to officially launch AttraX Putty for surgical use in the U.S. and expect it to be a cornerstone of our expanding biologics portfolio, ” Pat Miles, NuVasive’s president and COO, commented in the news release. “AttraX Putty has helped improve outcomes for more than 20, 000 spine patients worldwide, and we are pleased to now bring this biologic to market in the United States. Today’s launch is another example of NuVasive’s continued commitment to invest in industry-leading innovation that deliver the best possible patient outcomes.”

“AttraX Putty has shown promising results in pre-clinical models, highlighted by increased bone formation when compared to traditional osteoconductive synthetic scaffolds. The significant clinical experience with AttraX Putty outside the United States and extensive scientific pre-clinical study is an exciting and promising combination. I am looking forward to having access to this unique technology in my practice, for the benefit of my patients, ” said Robert Eastlack M.D., orthopedic surgeon at Scripps Clinic in La Jolla, California.

Mark Ojeda, vice president of Global Integrated Products & Services, told OTW, “Over the next 12 months, we expect to see significant adoption of AttraX Putty and increased share within the synthetic bone graft space as surgeons embrace the clinical benefits of AttraX Putty’s unique biotextured surface structure and intraoperative ease of use.”

“Surface topography at a cellular level has been validated as a key driver of bone formation, and its importance has long been recognized in the surface finishes of bone-contacting implants. With the biotextured surface features of AttraX Putty, surgeons can now realize the benefits of an advanced surface technology in a resorbable calcium phosphate bone graft.”